Multimedia Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug

KYBELLA(TM) (deoxycholic acid) Injection Significantly Improves Submental Fullness, or "Double Chin"

Print
| Source: KYTHERA Biopharmaceuticals, Inc.
video-release

Keith Leonard, Frederick Beddingfield


Amy - KYBELLA(TM) Clinical Trial Patient


Derek Jones


WESTLAKE VILLAGE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH), issued a release on Wednesday, April 29, with the headline "Photo Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug." The company is updating this release to include videos, which accompany the release issued yesterday.

Videos accompanying this release are available at:

http://www.globenewswire.com/newsroom/prs/?pkgid=32574

http://www.globenewswire.com/newsroom/prs/?pkgid=32575

http://www.globenewswire.com/newsroom/prs/?pkgid=32576

Media Contact:
Ashley Cadle
Tel: (310) 463-0143
a.cadle@togorun.com

Investor Contact:
Heather Rowe
Director, Investor Relations
Tel: (818) 587-4559
hrowe@kytherabiopharma.com